Drug Trial Radar · NCT06083129
Phase III Study Comparing GVHD Prophylaxis With ATG-thymoglobulin to ATLG-grafalon in Elderly Patients With Acute Myeloid Leukemia or Myelodysplasic Syndrome and Receiving an Allogeneic Hematopoietic Stem Cell Transplantation With a 10/10 HLA Matched Unrelated Donor
Last checked: Nov 20, 2026Latest source record: Apr 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
324
Planned (sponsor's estimate)
Start
Nov 28, 2023
Primary completion
Nov 28, 2028
Study completion Nov 28, 2028
Sponsor
- Lead sponsor
- Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 13, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 50 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only curative therapy in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Most of the patients requiring an allo-HSCT are above 50 years of age and are transplanted with a reduced intensity conditioning (RIC) regimen. The optimal RIC and Graft Versus Host Disease (GVHD) prophylaxis regimen allowing a good control of the disease while preventing GVHD remains to be determined for elderly patients. A phase III trial comparing the conventional RIC fludarabine-busulfan 2 days to fludarabine-treosulfan demonstrated an advantage for the flu-treosulfan arm in terms of event free survival (EFS), that should therefore be considered as the new standard of RIC regimen for AML and MDS. GVHD prevention has a crucial role in post-transplant outcomes by potentially interfering with the graft-versus-leukemia (GVL) effect and immune reconstitution. Anti-thymocyte globulins (ATG) are recommended to reduce the risk of acute and chronic GVHD in transplants performed with matched unrelated donors. However, the optimal type of ATG between the 2 approved brands (ATG-thymoglobulin and ATLG-grafalon) displaying distinct characteristics and the optimal dose of ATG are still unknown. In a retrospective study of patients transplanted mainly with RIC with matched related and unrelated donors for haematological malignancies, Anti-T lymphocyte globulin (ATLG) was associated with a reduction of grade II-IV acute GVHD in comparison to ATG without increasing the incidence of relapse. This phase III randomised study propose to compare GVHD prevention with ATG versus ATLG in AML and MDS patients above 50 years of age transplanted with a matched unrelated donor following a fludarabine-treosulfan RIC, with the hypothesis that ATLG would better control GVHD in this population of patients thus limiting the risk of morbidity and mortality of the procedure.
Conditions
- GVHD
Interventions
GrafalonDrug
10 mg/Kg/day IV for 3 consecutive days (day-3 to -1 before transplantation)
ThymoglobulinDrug
2.5 mg/Kg/day IV for 2 consecutive days (day-3 and -2 before transplantation)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of grade II-IV acute Graft Versus Host Disease (GVHD) according to the Mount Sinai Acute GVHD International Consortium (MAGIC) classificationTime frame: At day 100 post-transplantation
Locations
28 sites in 1 country. Site status is shown where the registry gives one.
CHU Amiens
Amiens, France · Recruiting
CHU Angers
Angers, France · Recruiting
CHU Besançon
Besançon, France · Recruiting
CHU Bordeaux
Bordeaux, France · Recruiting
CHU Brest
Brest, France · Recruiting
CHU Caen
Caen, France · Recruiting
CHU Clermont-Ferrand
Clermont-Ferrand, France · Recruiting
Hôpital Henri Mondor AP-HP
Créteil, France · Not yet recruiting
CHU Grenoble
Grenoble, France · Recruiting
CHU Lille
Lille, France · Recruiting
CHU Limoges
Limoges, France · Recruiting
CHU Lyon Sud
Lyon, France · Recruiting
IPC Marseille
Marseille, France · Recruiting
CHU Montpellier
Montpellier, France · Recruiting
CHRU Nancy
Nancy, France · Recruiting
CHU Nantes
Nantes, France · Recruiting
CHU Nice
Nice, France · Recruiting
Hôpital La Pitié Salpêtrière AP-HP
Paris, France · Recruiting
Hôpital Necker AP-HP
Paris, France · Recruiting
Hôpital Saint Louis AP-HP
Paris, France · Recruiting
Hôpital Saint-Antoine AP-HP
Paris, France · Recruiting
CHU Poitiers
Poitiers, France · Recruiting
CHU Rennes
Rennes, France · Recruiting
CHU Saint Etienne
Saint-Etienne, France · Recruiting
CHRU Strasbourg
Strasbourg, France · Recruiting
Oncopole Toulouse
Toulouse, France · Recruiting
CHRU Tours
Tours, France · Not yet recruiting
Institut Gustave Roussy
Villejuif, France · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.